|
Helicos BioSciences Corporation, was a publicly traded life science company headquartered in Cambridge, Massachusetts focused on genetic analysis technologies for the research, drug discovery and diagnostic markets. The firm's Helicos Genetic Analysis Platform was the first DNA-sequencing instrument to operate by imaging individual DNA molecules. In May 2010, the company announced a 50% layoff and a re-focusing on molecular diagnostics. After long financial troubles, in April 2010, Helicos was delisted from NASDAQ. Helicos was co-founded in 2003 by life science entrepreneur Stanley Lapidus, Stephen Quake, and Noubar Afeyan with investments from Atlas Venture, Flagship Ventures, Highland Capital Partners, MPM Capital, and Versant Ventures. Helicos's technology images the extension of individual DNA molecules using a defined primer and individual fluorescently labeled nucleotides, which contain a "Virtual Terminator" preventing incorporation of multiple nucleotides per cycle. The "Virtual Terminator" technology was developed by Dr. Suhaib Siddiqi, while at Helicos Biosciences. In the August 2009 issue of Nature Biotechnology, Dr. Stephen Quake, a professor of bioengineering at Stanford University and a co-founder of Helicos BioSciences, sequenced his own genome, using Single Molecule Sequencing for under $50,000 in reagents. On November 15, 2012, Helicos BioSciences filed for Chapter 11 bankruptcy. ==See also== *Helicos single molecule fluorescent sequencing *Pharmacogenomics *Genetic counseling *Genomics 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Helicos Biosciences」の詳細全文を読む スポンサード リンク
|